

CONFERENCE SCHEDULE

TUESDAY, APRIL 24, 2018

7:00pm Opening Welcome Reception and Cocktail Party

WEDNESDAY, APRIL 25, 2018

8:00 Registration / Coffee Service

SESSION 1: WELCOME AND KEYNOTE SPEAKERS

9:00 **Welcome**

*Keith Kaye, MD, MPH; Michigan Medicine and
Jaime Lora-Tamayo, MD, PhD; Madrid Hospital Chair*

9:15 **Polymyxins in a New Era of XDR Gram-Negatives: Polymyxin
Accomplishments in the Last Decade**

David Paterson, MD, PhD

9:45 **State of the Art of Optimizing Polymyxin Therapy: Knowns and Unknowns**

Jian Li, PhD

SESSION 2: AN UPDATE IN CLINICAL TRIALS COMPARING COLISTIN MONOTHERAPY TO COMBINATION THERAPY

10:20 **Colistin Use in Critically-Ill Patients: Lessons From Recent Trials**

Emanuele Durante Mangoni, MD

10:40 **OVERCOME**

Keith Kaye, MD, MPH

11:00 Break and Poster Viewing

SESSION 3: REGULATORY AND INDUSTRY ISSUES AND ACTIONS

11:15 **EMA Actions**

Marco Cavaleri, PhD

11:30 **FDA Strategies**

Sumathi Nambiar, MD, MPH

11:45 **Agricultural and Environment Implications for Polymyxin Use**

Ursula Theuretzbacher, PhD

12:00pm Lunch

SESSION 4: ORAL PRESENTATIONS (CO-SPONSORED WITH ISAP & EPASG)

1:30 10 Presentations at 8 Minutes with 2 Questions

3:30 Break and Poster Viewing

CONFERENCE SCHEDULE

SESSION 5: WHAT'S NEW IN THE CLINICAL MICROBIOLOGY LABORATORY

- 4:00 **What's New in Rapid Diagnostics and Susceptibility Testing**
Johan Mouton, MD, PhD
- 4:20 **EUCAST and CLSI Breakpoints**
Roger Nation, PhD
- 5:00 *Session Adjourns*
- 8:30 *Dinner Reception*

THURSDAY, APRIL 26, 2018

8:00am Registration / Coffee Service

SESSION 6: POLYMYXIN RESISTANCE

- 9:00 **Welcome**
Keith Kaye, MD, MPH
- 9:00 **MCR-1: The Phantom Menace**
Jianhua Liu, PhD
- 9:20 **Clinical Impact of Colistin Resistance**
Frederico Perez, MD
- 9:40 **Current novel polymyxin drug discovery and structure-activity relationships**
Tony Velkov, PhD

SESSION 7: THE LATEST ADVANCEMENTS IN UNDERSTANDING POLYMYXIN TOXICITIES

- 10:00 **Polymyxin-Induced Toxicity: Knowns and Unknowns**
Jian Li, PhD
- 10:20 **Strategies to Decrease Nephrotoxicity**
Jason Pogue, PharmD
- 10:40 **Emerging Polymyxin Toxicities: It Isn't All About the Kidneys**
Alexandre Zavascki, MD
- 11:00 *Break and Poster Viewing*

SESSION 8: COMBATING ANTIBACTERIAL RESISTANCE: NIH AND EU INITIATIVES

- 11:20 **Transatlantic Partnerships and the NIH**
Dennis Dixon, PhD, and Lanling Zou, MD
- 11:35 **The European Road Map Against Antimicrobial Resistance**
Ursula Theuretzbacher, PhD
- 11:50 *Lunch*

CONFERENCE SCHEDULE

SESSION 9: POLYMYXIN PERSPECTIVES AROUND THE WORLD

SESSION 9A: SPANISH ROUND TABLE IN COLLABORATION WITH 'SPANISH INFECTIOUS DISEASES SOCIETY'

- 1:00 **Colistin as the Last Resort Therapy in Extremely Drug Resistant Gram Negative Bacilli Infections: Lessons Learned**
Juan Pablo Horcajada, MD, PhD
- 1:15 **Colistin in the Treatment of Biofilm-Associate Infections: Pre-Clinical and Clinical Evidence**
Oscar Murillo, MD, PhD
- 1:30 **Polymyxins, Microbiology and Epidemiology: The Spanish Perspective**
Luis Martinez, MD, PhD

SESSION 9B: EMERGING POLYMYXIN USE: REPORTS FROM ASIA

- 1:45 **INDIA**
Sumanth Gandra, MD, MPH
- 2:05 **CHINA**
Qiwen Yang, PhD
- 2:25 **THAILAND**
Visanu Thamlikitkul, MD

SESSION 10: NEXT GENERATION PK/PD/TD

- 2:40 **Polymyxin PK/PD: To Infinity and Beyond**
Brian Tsuji, PharmD
- 3:00 **Is There a Therapeutic Window? Colistin or Polymyxin B**
Vincent Tam, PharmD
- 3:20 **TDM: The Next Frontier**
William Couet, PhD
- 3:40 Break

SESSION 11: POLYMYXIN GUIDELINES

- 3:55 **Overview**
- 4:00 **Colistin Dosing**
Roger Nation, PhD
- 4:30 **Polymyxin B Dosing**
Alexandre Zavascki, MD
- 5:00 **Combinations**
George Daikos, MD, Brian Tsuji, PharmD, and Jason Pogue, PharmD
- 5:30 **Aerosolized Use**
Keith Kaye, MD, MPH
- 5:45 **Intrathecal Use**
Helen Giamarellou, MD
- 6:00 Round Table Discussion
- 6:15 Course Adjourns